ArticleNucleic acids research2025
Diverse RNA viral effectors converge on facilitation of AGO4 degradation to promote infection.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
ARGONAUTE4 (AGO4)-mediated RNA-directed DNA methylation (RdDM) defends against DNA viruses by methylating their genomes. However, there is limited information available regarding RNA viruses. Here, we show that OsAGO4 has antiviral immunity against two different types of RNA viruses, rice stripe virus (RSV, Tenuivirus) and Southern rice black streaked dwarf virus (SRBSDV, Fijivirus). To facilitate infection, the evolutionarily distinct viral effectors RSV P2 and SRBSDV SP8 both targeted OsAGO4 for degradation. These unrelated viral proteins both recruited the F-box protein OsFBX68 to promote their association with OsAGO4, resulting in enhanced OsAGO4 degradation. In summary, our findings elucidated OsAGO4-mediated antiviral defense and reveal new mechanisms by which diverse RNA viral effectors exploit OsAGO4 to promote infection using a common counter-defense strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.